Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns “Buy” Rating from D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $2.00 price objective on the stock. D. Boral Capital’s price target indicates a potential upside of 8.70% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Monday, November 24th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $4.67.

Lineage Cell Therapeutics Price Performance

Shares of Lineage Cell Therapeutics stock opened at $1.84 on Monday. The stock’s 50 day simple moving average is $1.68 and its 200-day simple moving average is $1.56. The stock has a market cap of $423.81 million, a P/E ratio of -6.34 and a beta of 1.80. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $2.09.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in Lineage Cell Therapeutics during the fourth quarter worth about $25,000. Citizens Financial Group Inc. RI purchased a new position in Lineage Cell Therapeutics in the third quarter valued at about $25,000. Jump Financial LLC acquired a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter valued at approximately $28,000. Cannon Global Investment Management LLC purchased a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $30,000. Finally, Integrity Alliance LLC. boosted its stake in shares of Lineage Cell Therapeutics by 75.0% during the 2nd quarter. Integrity Alliance LLC. now owns 35,000 shares of the company’s stock worth $32,000 after acquiring an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.